BACKGROUND: Canada's Neo Rhino Party, a joke political party created in 2006 as a successor to the Parti Rhinocéros, is planning a new regulation to repeal the law of gravity, which could have an important impact on diseases attributable to gravity on earth. METHODS: We sought to estimate the number of quality-adjusted life-years that would be saved if the proposed regulation is passed and determine the cost-effectiveness of adapting Boris Volfson's antigravity machine for use on earth. We performed an economic analysis using a hidden Markov model. RESULTS: Our results suggest that a microgravity environment would save over 2 million quality-adjusted life-years. The cost for every quality-adjusted life-year saved is estimated to be $328. INTERPRETATION: Microgravity is the solution to the health care crisis in Canada. In addition, using technological, statistical and medical jargon gives us the opportunity to defy the laws of physics, mathematics and medicine.
BACKGROUND: Canada's Neo Rhino Party, a joke political party created in 2006 as a successor to the Parti Rhinocéros, is planning a new regulation to repeal the law of gravity, which could have an important impact on diseases attributable to gravity on earth. METHODS: We sought to estimate the number of quality-adjusted life-years that would be saved if the proposed regulation is passed and determine the cost-effectiveness of adapting Boris Volfson's antigravity machine for use on earth. We performed an economic analysis using a hidden Markov model. RESULTS: Our results suggest that a microgravity environment would save over 2 million quality-adjusted life-years. The cost for every quality-adjusted life-year saved is estimated to be $328. INTERPRETATION: Microgravity is the solution to the health care crisis in Canada. In addition, using technological, statistical and medical jargon gives us the opportunity to defy the laws of physics, mathematics and medicine.
Authors: George M Pantalos; Thomas E Bennett; M Keith Sharp; Stewart J Woodruff; Sean D O'Leary; Kevin J Gillars; Thomas Schurfranz; Scott D Everett; Mark Lemon; John Schwartz Journal: Curr Pharm Biotechnol Date: 2005-08 Impact factor: 2.837